--- title: Medical Device Packaging Design: MDR Requirements and Standards description: Packaging is a regulated component of the medical device. Here is what MDR Annex I and the EN ISO 11607 series actually require, and how to pass audit. authors: Tibor Zechmeister, Felix Lenhard category: Electrical Safety & Systems Engineering primary_keyword: medical device packaging design MDR canonical_url: https://zechmeister-solutions.com/en/blog/medical-device-packaging-design-mdr source: zechmeister-solutions.com license: All rights reserved. Content may be cited with attribution and a link to the canonical URL. --- # Medical Device Packaging Design: MDR Requirements and Standards *By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.* > **Under the MDR, packaging is not a wrapper. It is a regulated component of the device. For sterile devices, the sterile barrier system must maintain sterility until the point of use, and MDR Annex I §11.5 makes this an explicit General Safety and Performance Requirement. The EN ISO 11607 series is the harmonised standard that tells you how to prove it.** **By Tibor Zechmeister and Felix Lenhard.** ## TL;DR - MDR Annex I §11.5 requires that devices delivered in a sterile state be designed, manufactured, and packed in a non-reusable pack and by appropriate procedures to ensure that they are sterile when placed on the market and remain sterile under transport and storage conditions until the protective packaging is damaged or opened. - The harmonised standard family is EN ISO 11607-1 and -2 (packaging for terminally sterilized medical devices. Requirements for materials, sterile barrier systems, and packaging systems; and validation requirements for forming, sealing, and assembly processes). - Packaging validation has two distinct halves: performance (does the sterile barrier work after aging and transport?) and process (is the sealing process in control?). - Shelf life is a packaging claim as much as a device claim. Accelerated aging per ASTM F1980 plus real-time aging runs in parallel. - Transport simulation per ASTM D4169 or ISTA is part of performance qualification, not an afterthought. - The most common packaging audit finding is missing validation of the sealing process. Not the design itself. ## Why this matters A seed-stage surgical tools company had CE-marked a Class IIa instrument kit. Their sterile barrier was a Tyvek lid heat-sealed to a thermoformed tray. It worked. The devices came out sterile. At their first Notified Body surveillance audit, the auditor asked three questions: what are your sealing parameters, how did you validate them, and where is your seal strength data after aging and transport. They had a work instruction that said "seal at 170 degrees for 2 seconds." They had no IQ, OQ, PQ for the sealer. They had no aged seal strength data. Nonconformity. Thirty days to respond. Packaging failures rarely surface in development. They surface in audit, in the field, or in a recall. A package that looks fine on the production line can fail after six weeks in a distribution van or eighteen months on a hospital shelf. The MDR does not care that your device was sterile when it left your factory. It cares whether it is sterile when the surgeon opens it. ## What MDR actually says The relevant text is in MDR (EU) 2017/745 Annex I. The General Safety and Performance Requirements. **Annex I §11. Infection and microbial contamination.** This section covers the broad requirement to minimize infection risk to patients, users, and third parties. It includes design for ease of handling, reduction of microbial leakage, and for devices delivered in a sterile state, specific packaging obligations. **Annex I §11.5** specifically requires: "Devices delivered in a sterile state shall be designed, manufactured and packaged in a non-reusable pack and/or according to appropriate procedures to ensure that they are sterile when placed on the market and remain sterile, under the storage and transport conditions specified by the manufacturer, until that packaging is damaged or opened." **Annex I §11.6** adds that devices delivered in a sterile state must be processed, packed, and sterilized using appropriate and validated methods. **Annex I §11.7** requires that devices intended for sterilization must be manufactured and packaged in appropriate and controlled conditions and facilities. Beyond the sterile barrier, MDR Annex I also touches packaging indirectly. **Chapter III §23** (information supplied by the manufacturer) requires that the label include, among other things, an indication if the device is sterile, the sterilization method, batch code or serial number, date of manufacture, expiry date or date by which the device should be used safely, and any special storage and handling conditions. That information lives on the packaging. ### The standard that does the work EN ISO 11607 is the harmonised standard for packaging of terminally sterilized medical devices. It has two parts: - **EN ISO 11607-1**. Packaging for terminally sterilized medical devices. Part 1: Requirements for materials, sterile barrier systems and packaging systems. Covers material selection, sterile barrier system design, performance testing, and stability. - **EN ISO 11607-2**. Part 2: Validation requirements for forming, sealing and assembly processes. Covers the IQ, OQ, PQ of the packaging process itself. Both together cover the full problem. Part 1 asks: is your packaging design fit for purpose? Part 2 asks: can you reliably make it that way, every time? ## A worked example A single-use laparoscopic instrument, Class IIa, terminally sterilized by ethylene oxide. The sterile barrier system is a formed PETG tray with a Tyvek 1073B lid, heat-sealed on a rotary sealer. The secondary packaging is a printed folding carton. Claimed shelf life: 3 years. **Design qualification (EN ISO 11607-1):** - Material selection with justification: PETG compatible with EtO; Tyvek 1073B is the industry standard for EtO porous lid stock. - Initial integrity tests on unaged samples: visual inspection, dye penetration (ASTM F1929), bubble emission (ASTM F2096), seal strength (ASTM F88). - Distribution simulation on unaged samples per ASTM D4169 DC13 (single-package distribution cycle). - Aging program: real-time at 23 C / 50 percent RH for 36 months plus accelerated aging per ASTM F1980 at 55 C equivalent to 3 years in approximately 55 days. - Post-aging and post-distribution testing repeats the integrity and seal strength tests. **Process validation (EN ISO 11607-2):** - Installation Qualification (IQ) of the rotary sealer: documentation that the machine is installed per specification, calibrated, with approved utilities. - Operational Qualification (OQ): define the sealing process window. Run low, nominal, and high conditions for temperature, pressure, and dwell time. For each combination, test seal strength and integrity. Identify the acceptable operating range. - Performance Qualification (PQ): three consecutive production runs at nominal settings produce packages that meet all acceptance criteria. Operators trained to the validated procedure. - Ongoing process monitoring: seal peel strength sampling per batch, visual inspection of every seal, periodic re-qualification. **Risk management interface (EN ISO 14971:2019+A11:2021):** - Hazard: loss of sterile barrier during transport. Risk control: validated distribution simulation plus field feedback via PMS. - Hazard: seal failure from operator variation. Risk control: PQ-validated parameter window with locked-down recipe and sampling. - Hazard: material degradation over shelf life. Risk control: real-time and accelerated aging data supporting the expiry claim. **Technical documentation output:** The tech file contains the packaging specification, the DQ / IQ / OQ / PQ reports, aging data, distribution simulation reports, the risk management file entries, the label artwork, and the sterile barrier system validation summary. At audit, the Notified Body will ask for all of it. ## The Subtract to Ship playbook **1. Treat packaging as a design input, not an afterthought.** Add packaging to your design input list alongside electrical safety, biocompatibility, and usability. Assign an owner. Packaging decisions made in the last month of development always cost more than packaging decisions made in the first month. **2. Pick standard materials.** PETG trays with Tyvek lids for EtO. HDPE pouches for low-dose gamma. There is no prize for inventing a new sterile barrier. Every deviation from common materials extends validation time by months. **3. Buy a proven sealer, not a custom one.** Medical-grade rotary and tray sealers from established suppliers come with IQ/OQ templates. Custom-built sealers do not. The cost of the machine is trivial compared to the cost of validating it. **4. Plan aging before you start building.** Real-time aging takes as long as your shelf life claim. Accelerated aging per ASTM F1980 is a bridge, not a replacement. If you want a 3-year shelf life, you start aging samples 3 years before your last PMS update. Notified Bodies increasingly require real-time data to confirm accelerated predictions. **5. Run distribution simulation early.** A single ASTM D4169 or ISTA 3A run on an unaged package costs a few thousand euros and can expose design flaws while fixes are still cheap. Book this before your first clinical batch. **6. Validate the process, not just the product.** Notified Bodies rarely challenge a packaging design that uses common materials. They frequently challenge packaging process validation that does not exist. IQ/OQ/PQ per EN ISO 11607-2 is the audit target. **7. Connect packaging to PMS.** Packaging failures in the field (wet packs, seal peels on arrival, broken pouches) are PMS inputs. Your complaint handling procedure must catch them, your trend reporting must include them, and your PMS plan must cover them. **8. Document every label element against MDR Annex I Chapter III §23.** Expiry date, batch number, sterilization method indicator, storage conditions. The label is not marketing. It is regulatory. ## Reality Check 1. Do you have a packaging specification document that treats the sterile barrier system as a regulated component with controlled drawings, materials, and approval? 2. Have you performed design qualification per EN ISO 11607-1 covering integrity, seal strength, aging, and distribution simulation? 3. Is your sealing process IQ/OQ/PQ validated per EN ISO 11607-2, with a defined operating window and documented PQ runs? 4. Do you have real-time aging data (not just accelerated) supporting your current shelf life claim? 5. Is packaging failure included as a hazard in your EN ISO 14971 risk management file, with specific controls traced to tests? 6. Does your label include every element required by MDR Annex I Chapter III §23, in the correct languages for the markets you ship to? 7. Do your PMS data sources capture packaging-related complaints and feed them into trend reporting? 8. If a Notified Body auditor asked to see your packaging validation package tomorrow, could you hand over DQ, IQ, OQ, PQ, aging, and distribution reports in under an hour? ## Frequently Asked Questions **Is EN ISO 11607 mandatory, or is it just one option?** EN ISO 11607-1 and -2 are harmonised standards under the MDR. Using them gives you presumption of conformity with the relevant parts of MDR Annex I §11.5 and §11.6. You are not legally required to use them, but deviating means you must demonstrate equivalence by another route, and no Notified Body will thank you for it. **Can I claim shelf life based purely on accelerated aging?** In principle yes, for your initial CE submission. In practice Notified Bodies expect you to continue real-time aging and update your dossier as real data becomes available. Several NBs now require at least some real-time data even at first submission. **Do I need to validate packaging if my device is not sterile?** EN ISO 11607 applies specifically to terminally sterilized devices. Non-sterile devices still need packaging that protects them during transport and storage (MDR Annex I §11.8), but the validation burden is lower and driven by risk management rather than the 11607 series. **What is the difference between a sterile barrier system and protective packaging?** The sterile barrier system is the minimum packaging that prevents microbial ingress and allows aseptic presentation. Protective packaging (outer cartons, shippers) protects the sterile barrier system during handling and transport. Both are part of the validated packaging system. **How often do I need to re-validate the packaging process?** After any significant change to materials, equipment, process parameters, or facility. Routine revalidation intervals (typically every 1 to 3 years) should be defined in your validation master plan. Field complaints indicating packaging issues trigger immediate review. **What about Unique Device Identification on the packaging?** UDI carriers must appear on the label and on all higher levels of packaging per MDR Articles 27-29. This is separate from the sterile barrier validation but lives on the same artwork. ## Related reading - [Sterilization validation documentation under MDR](/blog/sterilization-validation-documentation-mdr) – the process behind the sterile in sterile barrier. - [Shelf life and stability testing documentation](/blog/shelf-life-stability-testing-documentation) – how shelf life claims are built and defended. - [Transport and storage validation in the technical file](/blog/transport-storage-validation-tech-doc) – distribution simulation in detail. - [MDR labeling requirements](/blog/mdr-labeling-requirements) – what must appear on the carton and the pouch. - [MDR Annex I GSPR](/blog/mdr-annex-i-gspr) – the parent framework that §11.5 lives under. ## Sources 1. Regulation (EU) 2017/745 on medical devices, consolidated text. Annex I §11.5, §11.6, §11.7, Chapter III §23. 2. EN ISO 11607-1. Packaging for terminally sterilized medical devices. Part 1: Requirements for materials, sterile barrier systems and packaging systems. 3. EN ISO 11607-2. Packaging for terminally sterilized medical devices. Part 2: Validation requirements for forming, sealing and assembly processes. 4. EN ISO 14971:2019+A11:2021. Medical devices. Application of risk management to medical devices. --- *This post is part of the [Electrical Safety & Systems Engineering](https://zechmeister-solutions.com/en/blog/category/electrical-safety) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*